Specialty Pharma Journal Specialty, Precision & Technology
WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of …
Tag Archives: Sanofi
May, 2017
-
24 May
Regeneron and Sanofi Announce FDA Approval of Kevzara for Treatment of Rheumatoid Arthritis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), …
-
3 May
Eighty Percent of RA Patients Report Life-Altering Pain Daily or Multiple Times a Week Despite Treatment, According to Survey Results
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., May 2, 2017 /PRNewswire/ — Honestly RA, a new survey of more than 1,000 people in the United States living with rheumatoid arthritis (RA), found that even after treatment, approximately 80 percent of RA patients experience pain daily or multiple times per week.1 Conducted by …
April, 2017
-
26 April
New Data from Genzyme’s Phase 3 Study Suggest Positive Effects of Aubagio on Cortical Gray Matter Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® (teriflunomide) on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology (AAN) …
-
24 April
FDA Approves Sanofi’s Thymoglobulin for Prevention of Acute Kidney Transplant Rejection
BRIDGEWATER, N.J., April 24, 2017 /PRNewswire/ — Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved Thymoglobulin® [anti-thymocyte globulin (rabbit)], for use in conjunction with concomitant immunosuppression in the prophylaxis, or prevention, of acute rejection in patients receiving a kidney transplant. Kidney disease is the ninth leading cause …
February, 2017
-
10 February
Appeals Court Grants Stay of Permanent Injunction for Praluent During Appeals Process
Paris, France and Tarrytown, New York – February 8, 2017 – Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) and Sanofi announced today that the United States Court of Appeals for the Federal Circuit has stayed (suspended) the permanent injunction for Praluent® (alirocumab) Injection pending the companies’ appeal. This ruling (available here) means …
January, 2017
-
23 January
Enteris BioPharma and Sanofi Enter Deal to Develop Oral Diabetes Drug
BOONTON, N.J., Jan. 23, 2017 /PRNewswire/ — Enteris BioPharma, Inc., announced today the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides. Joel Tune, Chief …
November, 2016
-
22 November
FDA Approves Sanofi’s Soliqua for Treatment of Type 2 Diabetes
Paris, France – November 21, 2016 – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua (TM) 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 …
-
14 November
Sanofi Genzyme to Co-Develop and Co-Commercialize Hemophilia Candidate with Alnylam
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced that, pursuant to the companies’ global alliance signed in January 2014, Sanofi Genzyme elected to opt in to co-develop (through Sanofi R&D) and co-commercialize fitusiran, an investigational RNAi therapeutic for the treatment of hemophilia and rare bleeding …
October, 2016
-
31 October
FDA Rejects Sanofi and Regeneron’s Rheumatoid Arthritis Drug due to Manufacturing Concerns
Paris and Tarrytown, N.Y. – October 28, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Applications (BLA) for sarilumab, an investigational interleukin-6 receptor (IL-6R) antibody for the treatment of adult patients with …